The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TBC Roche Products Pty Ltd
Product name
TBC
Sponsor
Accepted date
May-2024
Active ingredients
inavolisib
Proposed indication
For the treatment of adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Application type
A (new medicine)
Publication date
May-2024